Business Description
Arbutus Biopharma Corp
NAICS : 325410
SIC : 3741
ISIN : CA03879J1003
Total Employee Number:
19Description
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 150.91 | |||||
Equity-to-Asset | 0.94 | |||||
Interest Coverage | 1803.41 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 31.65 | |||||
Beneish M-Score | 31.08 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -34.1 | |||||
3-Year EBITDA Growth Rate | 25.1 | |||||
3-Year EPS without NRI Growth Rate | 36.3 | |||||
3-Year FCF Growth Rate | 4.5 | |||||
3-Year Book Growth Rate | -22.9 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 54.26 | |||||
Quick Ratio | 54.26 | |||||
Cash Ratio | 18.65 | |||||
Days Sales Outstanding | 2.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.9 | |||||
Shareholder Yield % | 0.06 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | 81.01 | |||||
Net Margin % | 83.95 | |||||
EBITDA Margin % | 84.02 | |||||
FCF Margin % | -17.95 | |||||
OCF Margin % | -17.95 | |||||
ROE % | 139.44 | |||||
ROA % | 116.5 | |||||
ROIC % | 396.56 | |||||
3-Year ROIIC % | -60.53 | |||||
ROC (Joel Greenblatt) % | 78061.17 | |||||
ROCE % | 123.88 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 5.87 | |||||
Forward PE Ratio | 11.21 | |||||
PE Ratio without NRI | 5.95 | |||||
PEG Ratio | 0.26 | |||||
PS Ratio | 4.96 | |||||
PB Ratio | 3.69 | |||||
Price-to-Tangible-Book | 3.69 | |||||
EV-to-EBIT | 5.39 | |||||
EV-to-EBITDA | 5.39 | |||||
EV-to-Revenue | 4.53 | |||||
EV-to-Forward-Revenue | 81.96 | |||||
EV-to-FCF | -25.25 | |||||
Price-to-GF-Value | 0.1 | |||||
Price-to-Median-PS-Value | 0.17 | |||||
Price-to-Graham-Number | 0.99 | |||||
| Price-to-Net-Current-Asset-Value | 3.69 | |||||
| Price-to-Net-Cash | 12.29 | |||||
Earnings Yield (Greenblatt) % | 18.55 | |||||
FCF Yield % | -3.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arbutus Biopharma Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 191.445 | ||
| EPS (TTM) ($) | 0.83 | ||
| Beta | 0.7304 | ||
| 3-Year Sharpe Ratio | 0.31 | ||
| 3-Year Sortino Ratio | 0.66 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 3.3188 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 3.3188 - 3.3188 | ||
| Shares Outstanding (Mil) | 197.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arbutus Biopharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arbutus Biopharma Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 131 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 32 days | ||
| General meeting for 2026 | 2026-05-26 10:00 | 3.32 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 3.32 (+0.00%) | ||
| Annual report for 2025 | 2026-03-23 | 3.32 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-23 | 3.32 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 3.32 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-06 | 3.32 (+0.00%) | ||
| General meeting for 2025 | 2025-05-21 10:00 | 3.32 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 3.32 (+0.00%) |
Show
Entries
Arbutus Biopharma Corp Frequently Asked Questions
What is Arbutus Biopharma Corp(LTS:0SGC)'s stock price today?
The current price of LTS:0SGC is $3.32. The 52 week high of LTS:0SGC is $3.32 and 52 week low is $3.32.
When is next earnings date of Arbutus Biopharma Corp(LTS:0SGC)?
The next earnings date of Arbutus Biopharma Corp(LTS:0SGC) is 2026-08-06 Est..
Does Arbutus Biopharma Corp(LTS:0SGC) pay dividends? If so, how much?
Arbutus Biopharma Corp(LTS:0SGC) does not pay dividend.
Press Release
Articles on Arbutus Biopharma Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers